Cure8 research brief
If local norepinephrine promotes neutrophil‑driven inflammation in UC, that could help explain disease progression in some patients and point to biomarkers (ADRB2‑rich neutrophils) that might predict response to anti‑TNF therapy.
Clinicians treating UC, researchers studying immune pathways or biomarkers in IBD, and patients receiving or considering biologic (anti‑TNF) therapy.
The paper combines human colon biopsies, a mouse DSS colitis model, targeted metabolomics, bulk and single‑cell RNA sequencing, spatial transcriptomics, and functional experiments.
Elevated colonic NE was found in patients and mice; local (enema) NE worsened colitis in mice by activating neutrophils through ADRB2, increasing intracellular ROS and promoting TNF‑mediated inflammatory signaling.
Clinically, the authors built a machine‑learning classifier from NE‑pathway genes with high accuracy for UC detection and observed that higher ADRB2‑neutrophil presence in pre‑treatment tissue correlated with favorable infliximab response.
The study authors propose ADRB2 antagonism as a potential therapeutic strategy, but this is presented as a mechanistic rationale rather than a tested treatment.
Results combine human tissue profiling and mouse experiments; proposed therapeutic implications (ADRB2 antagonists, biomarker‑guided biologic choice) are preliminary and need clinical trials.
Review the original publication for the complete reporting, methods, and context.
Conflict statement: Declaration of competing interest All the authors declare no conflicts of interest in this study.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
This meta-analysis pooled long‑term comparative data suggesting vedolizumab may have advantages over infliximab for treatment persistence, 12‑month remission, and safety in biologic‑naive ulcerative colitis — information...
Head-to-head comparisons between biologics are uncommon but useful for patients and clinicians deciding between agents. This study specifically compares ustekinumab and infliximab for remission, safety, and quality of...
The analysis compares rescue drugs used when severe ulcerative colitis doesn't respond to IV steroids — a high-stakes situation where avoiding colectomy matters.
